Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
GLP-1 receptor agonists — the class behind semaglutide and similar drugs — are showing survival benefits beyond just weight loss. A large real-world study found that obese adults with elevated inflammation markers who took GLP-1 RAs had a 20% lower risk of death, heart attack, or stroke compared to those on other weight-loss or diabetes medications. The survival gap was most striking for all-cause mortality, with a nearly 40% reduced hazard.
GLP-1 receptor agonists (GLP-1 RAs) — the drug class that includes semaglutide, liraglutide, and others — are already well-regarded for weight loss and blood sugar control. Now, a new real-world study suggests they may also offer meaningful protection against death and major cardiovascular events in obese patients who also have elevated inflammation.
Published in the American Journal of Cardiology, the observational cohort study drew on data from the TriNetX Global Collaborative Network, comparing over 50,000 propensity-matched patients on GLP-1 RAs against those taking metformin, orlistat, or phentermine. All participants had obesity (BMI ≥30) and elevated C-reactive protein (CRP) levels of 3–10 mg/L — a marker of chronic low-grade inflammation.
By the Numbers:
Why it matters: These findings suggest that inflammatory burden — measured by CRP — may help identify which obese patients stand to benefit most from GLP-1 RA therapy. Researchers are calling for prospective trials to confirm whether targeting inflammation is a key mechanism behind GLP-1 RAs' cardiovascular benefits.
